Coronary artery disease gene therapy - BioCardia
Latest Information Update: 07 Oct 2015
At a glance
- Originator BioCardia
- Class Gene therapies
- Mechanism of Action Cell replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Discontinued Coronary disorders
Most Recent Events
- 13 Mar 2007 Phase-II clinical trials in Coronary disorders in USA (unspecified route)